177 related articles for article (PubMed ID: 27436510)
1. Quantification of Somatic Chromosomal Rearrangements in Circulating Cell-Free DNA from Ovarian Cancers.
Harris FR; Kovtun IV; Smadbeck J; Multinu F; Jatoi A; Kosari F; Kalli KR; Murphy SJ; Halling GC; Johnson SH; Liu MC; Mariani A; Vasmatzis G
Sci Rep; 2016 Jul; 6():29831. PubMed ID: 27436510
[TBL] [Abstract][Full Text] [Related]
2. A field guide for cancer diagnostics using cell-free DNA: From principles to practice and clinical applications.
Volckmar AL; Sültmann H; Riediger A; Fioretos T; Schirmacher P; Endris V; Stenzinger A; Dietz S
Genes Chromosomes Cancer; 2018 Mar; 57(3):123-139. PubMed ID: 29205637
[TBL] [Abstract][Full Text] [Related]
3. Personalized Circulating Tumor DNA Biomarkers Dynamically Predict Treatment Response and Survival In Gynecologic Cancers.
Pereira E; Camacho-Vanegas O; Anand S; Sebra R; Catalina Camacho S; Garnar-Wortzel L; Nair N; Moshier E; Wooten M; Uzilov A; Chen R; Prasad-Hayes M; Zakashansky K; Beddoe AM; Schadt E; Dottino P; Martignetti JA
PLoS One; 2015; 10(12):e0145754. PubMed ID: 26717006
[TBL] [Abstract][Full Text] [Related]
4. A Targeted Q-PCR-Based Method for Point Mutation Testing by Analyzing Circulating DNA for Cancer Management Care.
Thierry AR
Methods Mol Biol; 2016; 1392():1-16. PubMed ID: 26843041
[TBL] [Abstract][Full Text] [Related]
5. Digital PCR of Genomic Rearrangements for Monitoring Circulating Tumour DNA.
Do H; Cameron D; Molania R; Thapa B; Rivalland G; Mitchell PL; Murone C; John T; Papenfuss A; Dobrovic A
Adv Exp Med Biol; 2016; 924():139-146. PubMed ID: 27753035
[TBL] [Abstract][Full Text] [Related]
6. Personalized tumor-specific DNA junctions to detect circulating tumor in patients with endometrial cancer.
Grassi T; Harris FR; Smadbeck JB; Murphy SJ; Block MS; Multinu F; Schaefer Klein JL; Zhang P; Karagouga G; Liu MC; Larish A; Lemens MA; Sommerfield MKS; Cappuccio S; Cheville JC; Vasmatzis G; Mariani A
PLoS One; 2021; 16(6):e0252390. PubMed ID: 34111149
[TBL] [Abstract][Full Text] [Related]
7. The Effect of Preservative and Temperature on the Analysis of Circulating Tumor DNA.
Parpart-Li S; Bartlett B; Popoli M; Adleff V; Tucker L; Steinberg R; Georgiadis A; Phallen J; Brahmer J; Azad N; Browner I; Laheru D; Velculescu VE; Sausen M; Diaz LA
Clin Cancer Res; 2017 May; 23(10):2471-2477. PubMed ID: 27827317
[No Abstract] [Full Text] [Related]
8. Reversion of BRCA1/2 Germline Mutations Detected in Circulating Tumor DNA From Patients With High-Grade Serous Ovarian Cancer.
Christie EL; Fereday S; Doig K; Pattnaik S; Dawson SJ; Bowtell DDL
J Clin Oncol; 2017 Apr; 35(12):1274-1280. PubMed ID: 28414925
[TBL] [Abstract][Full Text] [Related]
9. The value of fluorimetry (Qubit) and spectrophotometry (NanoDrop) in the quantification of cell-free DNA (cfDNA) in malignant melanoma and prostate cancer patients.
Ponti G; Maccaferri M; Manfredini M; Kaleci S; Mandrioli M; Pellacani G; Ozben T; Depenni R; Bianchi G; Pirola GM; Tomasi A
Clin Chim Acta; 2018 Apr; 479():14-19. PubMed ID: 29309771
[TBL] [Abstract][Full Text] [Related]
10. Evaluating the Utility of ctDNA in Detecting Residual Cancer and Predicting Recurrence in Patients with Serous Ovarian Cancer.
Zhu JW; Wong F; Szymiczek A; Ene GEV; Zhang S; May T; Narod SA; Kotsopoulos J; Akbari MR
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762691
[TBL] [Abstract][Full Text] [Related]
11. Circulating Tumor DNA Analysis for Liver Cancers and Its Usefulness as a Liquid Biopsy.
Ono A; Fujimoto A; Yamamoto Y; Akamatsu S; Hiraga N; Imamura M; Kawaoka T; Tsuge M; Abe H; Hayes CN; Miki D; Furuta M; Tsunoda T; Miyano S; Kubo M; Aikata H; Ochi H; Kawakami YI; Arihiro K; Ohdan H; Nakagawa H; Chayama K
Cell Mol Gastroenterol Hepatol; 2015 Sep; 1(5):516-534. PubMed ID: 28210698
[TBL] [Abstract][Full Text] [Related]
12. Establishing PNB-qPCR for quantifying minimal ctDNA concentrations during tumour resection.
Ehlert T; Tug S; Brahmer A; Neef V; Heid F; Werner C; Jansen-Winkeln B; Kneist W; Lang H; Gockel I; Simon P
Sci Rep; 2017 Aug; 7(1):8876. PubMed ID: 28827745
[TBL] [Abstract][Full Text] [Related]
13. Tissue-specific cell-free DNA degradation quantifies circulating tumor DNA burden.
Zhu G; Guo YA; Ho D; Poon P; Poh ZW; Wong PM; Gan A; Chang MM; Kleftogiannis D; Lau YT; Tay B; Lim WJ; Chua C; Tan TJ; Koo SL; Chong DQ; Yap YS; Tan I; Ng S; Skanderup AJ
Nat Commun; 2021 Apr; 12(1):2229. PubMed ID: 33850132
[TBL] [Abstract][Full Text] [Related]
14. Early Detection of Metastatic Relapse and Monitoring of Therapeutic Efficacy by Ultra-Deep Sequencing of Plasma Cell-Free DNA in Patients With Urothelial Bladder Carcinoma.
Christensen E; Birkenkamp-Demtröder K; Sethi H; Shchegrova S; Salari R; Nordentoft I; Wu HT; Knudsen M; Lamy P; Lindskrog SV; Taber A; Balcioglu M; Vang S; Assaf Z; Sharma S; Tin AS; Srinivasan R; Hafez D; Reinert T; Navarro S; Olson A; Ram R; Dashner S; Rabinowitz M; Billings P; Sigurjonsson S; Andersen CL; Swenerton R; Aleshin A; Zimmermann B; Agerbæk M; Lin CJ; Jensen JB; Dyrskjøt L
J Clin Oncol; 2019 Jun; 37(18):1547-1557. PubMed ID: 31059311
[TBL] [Abstract][Full Text] [Related]
15. Somatic alterations in circulating cell-free DNA of oesophageal carcinoma patients during primary staging are indicative for post-surgical tumour recurrence.
Pasternack H; Fassunke J; Plum PS; Chon SH; Hescheler DA; Gassa A; Merkelbach-Bruse S; Bruns CJ; Perner S; Hallek M; Büttner R; Bollschweiler E; Hölscher AH; Quaas A; Zander T; Weiss J; Alakus H
Sci Rep; 2018 Oct; 8(1):14941. PubMed ID: 30297788
[TBL] [Abstract][Full Text] [Related]
16. Using circulating cell-free DNA to monitor personalized cancer therapy.
Oellerich M; Schütz E; Beck J; Kanzow P; Plowman PN; Weiss GJ; Walson PD
Crit Rev Clin Lab Sci; 2017 May; 54(3):205-218. PubMed ID: 28393575
[TBL] [Abstract][Full Text] [Related]
17. Circulating Cell-Free DNA-Diagnostic and Prognostic Applications in Personalized Cancer Therapy.
Oellerich M; Schütz E; Beck J; Walson PD
Ther Drug Monit; 2019 Apr; 41(2):115-120. PubMed ID: 30883505
[TBL] [Abstract][Full Text] [Related]
18. Circulating cell-free DNA as a prognostic and predictive biomarker in non-small cell lung cancer.
Ai B; Liu H; Huang Y; Peng P
Oncotarget; 2016 Jul; 7(28):44583-44595. PubMed ID: 27323821
[TBL] [Abstract][Full Text] [Related]
19. Cell-free DNA mutations as biomarkers in breast cancer patients receiving tamoxifen.
Jansen MP; Martens JW; Helmijr JC; Beaufort CM; van Marion R; Krol NM; Monkhorst K; Trapman-Jansen AM; Meijer-van Gelder ME; Weerts MJ; Ramirez-Ardila DE; Dubbink HJ; Foekens JA; Sleijfer S; Berns EM
Oncotarget; 2016 Jul; 7(28):43412-43418. PubMed ID: 27270325
[TBL] [Abstract][Full Text] [Related]
20. PIK3CA mutations in serum DNA are predictive of recurrence in primary breast cancer patients.
Oshiro C; Kagara N; Naoi Y; Shimoda M; Shimomura A; Maruyama N; Shimazu K; Kim SJ; Noguchi S
Breast Cancer Res Treat; 2015 Apr; 150(2):299-307. PubMed ID: 25736040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
